02:10 PM EDT, 07/30/2025 (MT Newswires) -- Vyne Therapeutics ( VYNE ) said its phase 2b trial evaluating repibresib gel in nonsegmental vitiligo did not meet its primary endpoint.

Shares sank 70% following an increase in intraday trading volume to over 32.4 million from a daily average of about 693,000.

Anika Therapeutics ( ANIK ) said Wednesday that a phase 3 trial of its cartilage repair treatment, Hyalofast, failed to meet co-primary endpoints.

Shares plunged 25% as intraday trading volume rose to over 452,000 from a daily average of about 88,000.

Old Dominion Freight Line ( ODFL ) reported Q2 results below analyst forecasts, with both net income and revenue down from a year earlier.

Shares slumped 8.2%, with intraday trading volume surging to over 3.1 million from a daily average of about 1.7 million.

Price: 0.43, Change: -1.01, Percent Change: -70.00